<DOC>
	<DOCNO>NCT00747825</DOCNO>
	<brief_summary>This open-label , single dose study patient 18 year age old confirm metastatic melanoma . Up 12 patient enrol receive injection approximately 4.0 6.0 mCi ( 148-222 MBq ) 131-I-MIP-1145 administered via IV injection . The study consist single dosing day follow 7-day assessment period 21-day follow-up period . The total duration study screen final follow-up visit approximately 60 day .</brief_summary>
	<brief_title>Phase I Safety Dosimetry Study Patients With Confirmed Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Provide write informed consent willing comply protocol requirement 2 . Men woman 18 year age old 3 . Female patient must meet 1 follow criterion : childbearing potential documented medical history ( e.g. , tubal ligation hysterectomy ) , post menopausal minimum 1 year without menses Have negative serum beta human chorionic gonadotropin ( BHCG ) pregnancy test within 48 hour prior receive test article agree use medically acceptable form birth control , define abstinence use intrauterine device ( IUD ) , oral contraceptive , barrier spermicide , hormonal implant throughout 28 day study period . 4 . Male patient childbearing potential must agree use least one follow medically acceptable form birth control throughout 28 day study period ; abstinence , barrier acceptable , effective contraceptive method . 5 . Historical diagnosis ( surgical histological ) primary melanoma metastatic melanoma confirm histology and/or radiologically via MRI/CT . 6 . CT/MRI represent current measurable metastatic lesion ( within 6 12 week entry ; least one lesion &gt; 2cm long dimension ) 1 . Less 18 year age 2 . Pregnant breastfeed 3 . Inadequate venous access ( defined contralateral antecubital equivalent venous access site require study drug injection PK blood sampling , respectively ) 4 . Uncontrolled glaucoma retinopathy ( e.g . macular degeneration ) treat past year 5 . Cataracts lens opacity 6 . Any ophthalmologic intervention within last 30 day ( e.g. , cataract extraction , laser procedure equivalent , antiVEGF treatment macular degeneration . Topical treatment include antibiotic conjunctivitis allow . ) 7 . Patient receive external beam therapy chemotherapy within last 30 day 8 . Any history head neck radiotherapy 9 . Karnofsky performance status less 60 ( ECOG status &gt; 2 ) 10 . Serum creatinine great equal 2.0 mg/dL 11 . Total bilirubin great equal 1.5 time upper limit normal 12 . SGOT/AST SGPT/ALT great equal 3 time upper limit normal ( patient metastatic liver disease eligible transaminase elevation &gt; 5 time upper limit normal ) 13 . Received investigational compound and/or medical device within 30 day admission study 14 . Administered 99mTclabeled radioisotope &lt; 3 day prior image &lt; 7days prior image diagnostic radioisotope half live great 24 hour 15 . Any known allergy sensitivity iodine . Iodinated Xray contrast hypersensitivity exclusion . 16 . Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postinjection followup examination 17 . Determined Investigator clinically unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>cancer</keyword>
	<keyword>oncology</keyword>
	<keyword>melanoma</keyword>
	<keyword>tumor</keyword>
</DOC>